Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Long-Term Investments (2021 - 2024)

Historic Long-Term Investments for Pulmonx (LUNG) over the last 4 years, with Q1 2024 value amounting to $4.3 million.

  • Pulmonx's Long-Term Investments rose 6279.86% to $4.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $4.3 million, marking a year-over-year increase of 6279.86%. This contributed to the annual value of $14.4 million for FY2023, which is 14291.02% up from last year.
  • Pulmonx's Long-Term Investments amounted to $4.3 million in Q1 2024, which was up 6279.86% from $14.4 million recorded in Q4 2023.
  • Pulmonx's 5-year Long-Term Investments high stood at $23.3 million for Q3 2023, and its period low was $2.0 million during Q2 2021.
  • In the last 4 years, Pulmonx's Long-Term Investments had a median value of $5.3 million in 2022 and averaged $7.7 million.
  • Within the past 5 years, the most significant YoY rise in Pulmonx's Long-Term Investments was 16588.39% (2023), while the steepest drop was 5866.12% (2023).
  • Quarter analysis of 4 years shows Pulmonx's Long-Term Investments stood at $10.9 million in 2021, then crashed by 45.86% to $5.9 million in 2022, then skyrocketed by 142.91% to $14.4 million in 2023, then tumbled by 70.17% to $4.3 million in 2024.
  • Its Long-Term Investments stands at $4.3 million for Q1 2024, versus $14.4 million for Q4 2023 and $23.3 million for Q3 2023.